
Please try another search
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Name | Age | Since | Title |
---|---|---|---|
Daniel Joseph Levangie | 70 | 2010 | Independent Director |
Paul J. Clancy | 59 | 2021 | Independent Director |
James E. Doyle | 75 | 2014 | Lead Independent Director |
Shacey Petrovic | 47 | 2020 | Independent Director |
Katherine S. Zanotti | 66 | 2009 | Independent Director |
Kevin T. Conroy | 56 | 2009 | Chairman of The Board & CEO |
D. Scott Coward | 58 | 2015 | Director |
Michael J. Barber | 64 | 2024 | Independent Director |
Kimberly J. Popovits | 67 | 2025 | Independent Director |
Leslie L. Trigg | 54 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review